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Abstract 27 
The elucidation of the mechanisms directing β-cell mass regeneration and maintenance is of interest 28 
since the deficit of β-cell mass contributes to diabetes onset and progression. We previously found that 29 
the level of the microRNA miR-338-3p is decreased in pancreatic islets from rodent models displaying 30 
insulin resistance and compensatory β-cell mass expansion, including pregnant rats, diet-induced 31 
obese mice and db/db mice. Transfection of rat islet cells with oligonucleotides that specifically block 32 
miR-338-3p activity increased the fraction of proliferating β-cells in vitro and promoted survival under 33 
pro-apoptotic conditions without affecting the capacity of β-cells to release insulin in response to 34 
glucose. Here, we evaluated the role of miR-338-3p in vivo by injecting mice with an Adeno-35 
Associated viral (AAV) vector permitting specific sequestration of this microRNA in β-cells. We 36 
found that the AAV construct increased the fraction of proliferating β-cells confirming the data 37 
obtained in vitro. miR-338-3p is generated from an intron of the gene coding for Apoptosis-Associated 38 
Tyrosine Kinase (AATK). Similarly to miR-338-3p, we found that AATK is down-regulated in rat and 39 
human islets and INS832/13 β-cells in the presence of the cAMP-raising agents exendin-4, estradiol 40 
and a GPR30 agonist. Moreover, AATK expression is reduced in islets of insulin resistant animal 41 
models and selective silencing of AATK in INS832/13 cells by RNA interference promoted β-cell 42 
proliferation. The results point to a coordinated reduction of miR-338-3p and AATK under insulin 43 
resistance conditions and provide evidence for a cooperative action of the microRNA and its hosting 44 
gene in compensatory β-cell mass expansion. 45 
3 
Introduction 46 
MicroRNAs (miRNAs) form a large family of short (≈22nt) single‐stranded non‐coding RNAs which 47 
are critical posttranscriptional regulators of gene expression (1,2). These small RNA molecules 48 
function by partially pairing to the 3’ untranslated region (UTR) of target mRNAs thereby inhibiting 49 
their translation and/or stability. Numerous miRNAs have been shown to play major roles in the 50 
regulation of β-cell functions, including insulin secretion, proliferation and survival (3,4). Mammalian 51 
miRNAs are generated from diverse genomic locations and can be either intergenic and transcribed 52 
from their own independent unit or intronic and transcribed from introns of protein-coding genes or 53 
from introns of non-coding genes (5,6). Some intronic miRNAs are co-regulated with their hosting 54 
genes and have analogous functions, whereas others display opposite expression profiles and have 55 
antagonistic roles (7). Bioinformatic studies revealed that about one third of the intronic miRNAs 56 
possess their own promoters, while the others are co-transcribed with their hosting genes and are 57 
processed from the same primary transcript (8,9). 58 
Recently, we showed that miR-338-3p is down-regulated in islets under conditions of insulin 59 
resistance, such as pregnancy and obesity, and upon exposure of β-cells to 17-β estradiol and to the 60 
GLP1-analogue exendin-4. We also observed that blockade of miR-338-3p in vitro and in transplanted 61 
islets leads to increased β-cell proliferation and improved survival under pro-apoptotic conditions (10). 62 
However, the beneficial impact of reduced miR-338-3p activity on β-cell function in vivo remained to 63 
be proven. This particular miRNA is generated from the seventh intron of the Apoptosis-Associated 64 
Tyrosine Kinase (AATK) gene, also called Lemur Kinase 1 (LMTK1) (5). Recent studies in other cell 65 
systems have evidenced a co-regulation of miR-338-3p and its hosting gene, and this miRNA was 66 
proposed to serve the interest of AATK by silencing several genes that act antagonistically to AATK 67 
(11). Although, AATK has been shown to play a role in cell differentiation, growth and apoptosis (12-68 
17) its biological relevance in insulin-producing cells is unknown.69 
4 
The objective of our study was first to verify whether the proliferative effect of miR-338-3p observed 70 
in vitro is conserved in vivo and second, to determine whether the hosting gene AATK synergizes or 71 
antagonizes the action of the miRNA. 72 
5 
Materials and methods 73 
74 
Chemicals 75 
TNFα and IFNγ were from R&D Systems. IL-1β, Tnfrsf1b, exendin-4, 17-β estradiol, 3-Isobutyl-1-76 
methylxanthine (IBMX) and G1 were obtained from Sigma-Aldrich. 77 
78 
Animals 79 
Male and pregnant Wistar rats were obtained from Charles River laboratories and were housed on a 80 
12:12 h light-dark cycle in climate-controlled and pathogen-free facilities. 8-week-old male ICR mice 81 
were used to inject AAV8 intraductally. All procedures were performed in accordance with the 82 
National Institutes of Health guidelines, and were approved by the Swiss Research Councils and 83 
Veterinary Office and by the Ethics Committee in Animal and Human Experimentation of the 84 
Universitat Autònoma de Barcelona. Four week-old male C57BL/6 mice were purchased from Charles 85 
River Laboratories (Saint-Constant, QC, Canada) and fed a normal diet or HFD (Bio-Ser Diet number 86 
F3282, Frenchtown, NJ, USA; 60% [wt/wt] energy from fat) for 8 weeks. The detailed sources of 87 
db/db and diet-induced obese mice have been described previously (18,19). 88 
89 
Isolation and culture of islet cells 90 
Pancreatic islets were isolated as described (20) by collagenase digestion followed by purification on a 91 
Histopaque (Sigma-Aldrich) density gradient. The islets were first cultured overnight in RPMI 1640 92 
Glutamax medium (Invitrogen) supplemented with 10% fetal calf serum (FCS; Amimed), 50 U/ml 93 
penicillin, 50ug/ml streptomycin, 1 mmol/l Na Pyruvate and 250 μmol/l Hepes. Human islets were 94 
obtained from the Cell Isolation and Transplantation Center from the University of Geneva, through 95 
the ECIT “Islets for Research” distribution program supported by the Juvenile Diabetes Research 96 
Foundation. The use of human islets was approved by the Geneva institutional ethical committee. 97 
After isolation, the islets were kept in culture for one or two days before treatment. Whole human 98 
islets were cultured in CMRL medium (Invitrogen) supplemented with 10% FCS, 100 U/ml penicillin, 99 
6 
100μg/ml streptomycin, 2mmol/l glutamine and 250 μmol/l Hepes. Detailed information about the 100 
human islet preparations used in this study is presented in the Supplemental Table 3. 101 
102 
Transfection and modulation of miR-338-3p and AATK levels 103 
INS832/13 cells or MIN6B1 cells were transfected using Lipofectamine 2000
TM
 (Invitrogen) with 104 
single-stranded miScript miRNA inhibitors (Qiagen) that specifically block endogenous miR-338-3p 105 
or with the miScript miRNA reference inhibitor (Qiagen) as a negative control. To modulate the level 106 
of the hosting gene, the cells were transfected with a small interfering RNA (siRNA) duplex against 107 
AATK or with a custom-designed siRNA duplex against green fluorescent protein that was used as 108 
negative control. To experimentally sequester and inhibit the activity of miR-338-3p, MIN6B1 cells 109 
were transfected for three days with plasmids expressing enhanced green fluorescent protein (EGFP)-110 
labelled constructs driven by the Rat Insulin Promoter II (RIP-II) containing either a control sponge or 111 
the miR-338-3p sponge. 112 
113 
Measurement of miRNA and mRNA expression 114 
Mature miRNA expression was assessed by qRT-PCR using the miRCURY LNA
TM
 Universal RT 115 
microRNA PCR kit (Exiqon). miRNA primers were purchased from Exiqon. Messenger RNA 116 
expression was measured by conventional reverse transcription (Promega) followed by qRT-PCR 117 
(Biorad) with custom-designed primers (Microsynth). Primer sequences are available on request. 118 
miRNA expression was normalized to the level of U6 small nuclear ribonucleoprotein. mRNA 119 
expression was normalized to the amount of 18S present in the same samples. 120 
121 
Insulin secretion 122 
Three days after transfection, INS832/13 cells were pre-incubated during 30 minutes at 37°C in Krebs-123 
Ringer buffer (25 mM HEPES, pH 7.4, 127 mM NaCl, 4.7 mM KCl, 1 mM CaCl2, 1.2 mM KH2PO4, 124 
1.2 mM MgSO4 and 5 mM NaHCO3) containing 2 mmol/l glucose. The pre-incubation medium was 125 
discarded and the cells incubated for 45 minutes in the same buffer (basal condition) or with Krebs-126 
Ringer buffer containing 20 mmol/l glucose,  10 μM Forskolin and 100 μM IBMX (stimulatory 127 
7 
condition). At the end of the incubation period, the medium was collected and total cellular insulin 128 
contents recovered with ethanol acid (75% ethanol, 0.55% HCl). The amount of insulin in the samples 129 
was determined using an insulin enzyme immunoassay kit (ELISA, Mercodia).  130 
131 
Cell death assessment 132 
Three days after transfection, transfected INS832/13 or MIN6B1 cells were incubated with 1 μg/ml 133 
Hoechst 33342 (Invitrogen) during 1 minute. The fraction of cells displaying picnotic nuclei was 134 
scored under fluorescence microscopy (AxioCam MRc5, Zeiss). Apoptosis was triggered by exposing 135 
the cells during 24h to cytokines (10 ng/ml TNFα, 0.1 ng/ml IL-1β and 30 mg/ml IFNγ) or during 48h 136 
to culture medium containing 5% FCS and supplemented with 0.5 mmol/l palmitate bound to 0.5% 137 
BSA. 138 
139 
Proliferation assay 140 
Three days after transfection, transfected INS832/13 or MIN6B1 cells and rat islet cells cultured on 141 
Poly-L-lysine coated glass coverslips, were fixed with ice-cold methanol and permeabilized with 0.5% 142 
saponin (Sigma-Aldrich). The coverslips were incubated with a rabbit anti-Ki67 antibody (ab66155 143 
Abcam) at 1:1500 and then with goat anti-rabbit Alexa Fluor 488 (A11008 Invitrogen). Pictures were 144 
collected using a fluorescence microscope (AxioCam MRc5, Zeiss). 145 
146 
Protein extraction and western Blotting 147 
Proteins lysates (30-50 μg) from INS832/13 cells were separated on polyacrylamide gels and 148 
transferred to nitrocellulose membranes. The membranes were incubated overnight at 4°C with 149 
primary antibody against AATK (Ab100587 Abcam; 1:500), AKT (Cell Signaling #2920; 1:500), 150 
phospho-AKT (Cell Signaling #9275; 1:500) or against α-Tubulin (T9026 Sigma Aldrich, 1:10000). 151 
After one hour exposure to IRDye (Li-Cor® Biosciences), the bands were visualized via the Odyssey 152 
imaging system (Li-Cor® Biosciences). Band intensity was quantified by using ImageJ software. 153 
154 
155 
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156 
Recombinant AAV vectors 157 
Single-stranded AAV vectors of serotype 8 were generated by triple transfection of human embryonic 158 
kidney 293 cells and purified by the CsCl-based gradient method (21). Transgenes used expressed a 159 
construct coding for EGFP driven by the rat insulin promoter II (RIP-II) and carried either a sponge 160 
against miR-338-3p or against a scrambled sequence. Purified AAV vectors were dialyzed against 161 
PBS, filtered and stored at -80°C. Titers of viral genomes (vg) were determined by qRT-PCR as 162 
described (22). 163 
164 
Administration of AAV vectors 165 
Retrograde pancreatic intraductal injections were performed as described previously (23). Mice were 166 
anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg). A dose of 10
12
 vg/mouse (100 μL 167 
AAV solution/mouse) was intraductally administered. 168 
169 
Luciferase assays 170 
A miR-338-3p sensor plasmid was generated by cloning a sequence complementary to the miRNA 171 
between the EcoR1 and XhoI restriction sites of psiCHECK-1 (Promega). An analogous approach was 172 
used to generate the plasmid including the 3’UTR of rat Tnfrsf1b containing the putative binding site 173 
of miR-338-3p. Luciferase activity was measured in INS832/13 or MIN6B1 cells with a dual-174 
luciferase reporter assay (Promega, Madison, WI) three days after transfection. Renilla luciferase 175 
activity was normalized for transfection efficiency to the SV40-driven Firefly activity generated by the 176 
PGL3 promoter vector (Promega). 177 
178 
Immunohistochemistry 179 
Tissues were fixed for three days in 10% formalin, embedded in paraffin and sectioned. The pancreatic 180 
slices were then incubated overnight at 4°C with the following antibodies: 1:300 goat anti-GFP 181 
(ab6673 Abcam), 1:200 guinea pig anti-insulin (ab7842 Abcam) or 1:300 rabbit anti-Ki67 (ab66155 182 
Abcam). As secondary antibodies, biotinylated donkey anti-goat (sc-2042 Santa Cruz), streptavidin 183 
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Alexa Fluor 488 (S-11223 Molecular Probes), goat anti-guinea pig Alexa Fluor 555 (A21435 184 
Invitrogen), goat anti-rabbit Alexa Fluor 555 (A21428 Invitrogen) at 1:300 were used. Sections were 185 
counterstained with Hoechst 33342 (Invitrogen) for nuclear labeling. A Zeiss Axiovision fluorescence 186 
microscope was used. For measurement of β-cell proliferation, three pancreatic slices (200 μm apart) 187 
were stained with anti-Ki67 and anti-GFP antibodies, and nuclei were counterstained with Hoechst. 188 
Replicative cells were identified by double Ki67 and GFP immunostaining. The β-cell mass was 189 
calculated by multiplying pancreas weight by percentage of β-cell area. The percentage of β-cell area 190 
per pancreas was analyzed in three insulin-stained sections 200 μm apart, by dividing the area of all 191 
insulin positive cells in one section by the total area of that section. An islet was considered as infected 192 
by the viruses if at least one insulin-positive cell was also positive for EGFP. 193 
 194 
 Statistical analysis 195 
Statistical differences were tested using a Student’s t-test or, for multiple comparisons, with ANOVA 196 
followed by a post-doc Dunnett test, with a discriminating p value of 0.05 (SAS statistical package).  197 
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Results 198 
β-cell specific inhibition of miR-338-3p promotes cell proliferation in vivo 199 
To inhibit the activity of miR-338-3p in vivo, we engineered a “microRNA sponge” (24,25) capable of 200 
specifically inhibiting the activity of this miRNA in β-cells. Our construct is driven by the rat insulin 201 
promoter and contains the coding region of EGFP with 7 binding sites for miR-338-3p in the 3’UTR. 202 
By capturing miR-338-3p, the sponge prevents the interaction with the endogenous targets of the 203 
miRNA (Figure 1A). Indeed, the transfection of the miR-338-3p sponge in the insulin-secreting cell 204 
line MIN6B1 led to an increase in the expression of a luciferase reporter construct containing the 205 
binding site of the miRNA (Supplemental Fig. 1A) and reproduced the functional effects of anti-miR-206 
338-3p (10) resulting in an increased proliferation rate and enhanced survival under pro-apoptotic 207 
conditions (Supplemental Fig. 1B, C). To examine whether inhibition of miR-338-3p activity in vivo 208 
promotes the replication of β-cells, a dose of 1×1012 viral genomes/mouse of AAV8 vectors carrying 209 
the RIP-II-GFP-miR-338-3p sponge cassette or RIP-II-GFP-control sponge were injected into the 210 
pancreatic duct of adult ICR mice. One month after AAV administration, immunostaining revealed 211 
that more than 80% of the islets were transduced by these AAV8 vectors and expressed the construct 212 
(Figure 1B). Double immunostaining for insulin and GFP confirmed that the construct was exclusively 213 
expressed in β-cells. Quantification of the number of GFP+ β-cells demonstrated an average of 20% 214 
transduced β-cells (Figure 1C, D). The sponge was not expressed by glucagon-positive cells 215 
(Supplemental Fig. 2). The fraction of proliferating GFP
+
 β-cells receiving the control sponge was 216 
identical to that of non-transduced islet cells (Figure 1E). In contrast, the GFP
+
 β-cells receiving the 217 
AAV8-miR-338-3p sponge displayed a significant increase in the proliferation rate (Figure 1E, F). 218 
Consistent with these observations, the fraction of proliferating insulin-positive cells was increased in 219 
islets transduced with the miR-338-3p sponge compared to islets receiving the control sponge (Figure 220 
1G, H). One month after viral injection, no significant change in β-cell mass was observed between 221 
the two groups of mice (Figure 1I). Analysis of individual glycemic profiles revealed no differences 222 
between the two groups (data not shown). Overall the data demonstrate the conserved beneficial 223 
impact of reduced activity of miR-338-3p in promoting β-cell proliferation capacity in vivo. 224 
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miR-338-3p and its hosting gene AATK are co-regulated 225 
We previously reported reduced expression of miR-338-3p in islets of insulin resistant animals 226 
displaying compensatory β-cell mass expansion (10). Since this miRNA is encoded within one of the 227 
introns of AATK (Supplemental Fig. 3), we analyzed in the same samples the expression of the 228 
hosting gene. Similarly to miR-338-3p, we found that AATK mRNA decreases in islets of rats during 229 
pregnancy reaching the minimal level at day 14 of gestation (corresponding to the peak of β-cell mass 230 
expansion) and returned close to pre-pregnancy levels 3-days post-partum (Figure 2A). AATK 231 
expression is also reduced to a similar extent than miR-338-3p in islets of two animal models 232 
characterized by insulin resistance and compensatory β-cell mass expansion (Supplemental Tables 1 233 
and 2): 6 week-old pre-diabetic db/db mice (Figure 2B) and diet-induced obese mice fed a high-fat 234 
diet for 8 weeks (Figure 2C). These results suggest a common regulation of the expression profile of 235 
the gene coding for AATK and its intronic miRNA in pancreatic islets under conditions of insulin 236 
resistance.  237 
In view of these findings, to determine if miR-338-3p and AATK expression is coordinated we 238 
measured AATK mRNA levels in INS832/13 cells exposed to the cAMP-raising agent IBMX. We 239 
found that the changes in the level of miR-338-3p and AATK follow the same kinetics and are 240 
maximal after about 4 hours of treatment (Figure 3). We then exposed rat and human islets to 241 
estradiol, a hormone capable of eliciting a decrease of miR-338-3p expression by binding to its non-242 
canonical GPR30 receptor that activates the cAMP-dependent pathway (10). We found that exposure 243 
of rat and human islets to 17-β estradiol for 48 hours decreases the expression of AATK (Figure 4A, 244 
B). Treatment with G1, a specific GPR30 agonist, produced the same effect in rat islets (Figure 4C). 245 
GLP1 is also able to reduce the level of miR-338-3p by activating the cAMP-dependent pathway (10). 246 
In line with the effect of other hormones triggering cAMP-dependent signaling, the stable GLP1 247 
analog exendin-4 represses AATK levels both in rat and human islets (Figure 4D, E). A similar effect 248 
was also observed in INS832/13 cells both at the mRNA and at the protein level (Supplemental Fig. 249 
4).  250 
 251 
12 
 
Functional roles of AATK in insulin-secreting cells 252 
In order to investigate the functional role of AATK in β-cells and compare it to that of miR-338-3p, 253 
we used RNA interference to silence AATK mRNA and protein levels in INS832/13 cells. The siRNA 254 
treatment, faithfully reproduced the decrease of approximately 50% of AATK mRNA observed in 255 
islets of insulin resistant animal models, without affecting the level of miR-338-3p (Figure 5A). 256 
AATK protein levels were also reduced by about half (Figure 5B, C). A specific antisense LNA-257 
oligonucleotide (anti-miR) was also transiently transfected in INS832/13 cells to target and inhibit the 258 
endogenous miRNA without altering the mRNA level of AATK (Figure 5D). We first assessed the 259 
impact of the silencing of miR-338-3p and of its hosting gene on β-cell proliferation. Interestingly, 260 
inhibition of either miR-338-3p or AATK increased the proliferation of INS832/13 cells (Figure 6A) 261 
without significantly affecting insulin release (Figure 6B) and insulin content (Figure 6C). Moreover, 262 
in agreement with our previous results, the inhibition of miR-338-3p protected the cells against the 263 
toxic effects of pro-inflammatory cytokines and palmitate (Figure 6D, E). In contrast, the reduction of 264 
AATK did not promote cell survival under these pro-apoptotic conditions (Figure 6D, E). 265 
The precise mechanism through which miR-338-3p affects β-cell proliferation and survival remains to 266 
be elucidated. Functional analysis of the potential targets revealed enrichment in genes involved in 267 
cancer development, MAP kinase pathway and cytokine signaling (Supplemental Table 4). We indeed 268 
obtained evidence indicating that miR-338-3p directly targets Tnfrsf1b (26), potentially explaining 269 
part of the anti-apoptotic but not of the proliferative effect of the miRNA (Supplemental Fig. 5). We 270 
previously identified several key gene expression changes elicited by miR-338-3p blockade in rat and 271 
human islets (10) that mimic the mRNA expression profile observed in islets of insulin resistant 272 
animals (10,27-30). As expected, similar modifications of genes involved in proliferation and survival 273 
(Birc5, Foxm1, Cyclin D2, Igf1r, Irs2, Bcl2, Bcl-xl, Bad) were observed upon repression of miR-338-274 
3p in tumoral INS832/13 β-cells (Figure 6F) and led to the activation of the AKT signaling 275 
(Supplemental Fig. 6). Consistent with its functional impact on cell proliferation, silencing of AATK 276 
in INS832/13 cells led to an increase in the expression of Igf1r and Irs2, two genes that are part of an 277 
autocrine loop involved in regulating β-cell proliferation (31,32) (Figure 6F). In contrast, reduced 278 
13 
 
levels of AATK did not trigger any modification in the expression of the anti- or pro-apoptotic genes 279 
Bcl2, Bcl-xl and Bad (Figure 6F) as miR-338-3p did. Altogether these results strongly support the 280 
hypothesis of a cooperative action of miR-338-3p and its hosting gene AATK on β-cell proliferation 281 
and in promoting the expansion of the functional β-cell mass under insulin resistant conditions. 282 
  283 
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Discussion 284 
In the present study, we have identified β-cell specific down-regulation of miR-338-3p as a powerful 285 
strategy to promote β-cell proliferation in vivo. Furthermore, we extend our understanding of the 286 
regulation and functional role of the miR-338-3p hosting gene AATK. The results reveal a parallel 287 
down-regulation of the miRNA and its hosting gene in islets of insulin resistant animal models and in 288 
response to activation of the cAMP-dependent pathway. In addition, we were able to show that AATK 289 
contributes to the regulation of β-cell proliferation by activating signaling pathways that are common 290 
to those of the miRNA. 291 
Conventional knock-out (KO) mouse models are often used to study the role of miRNAs in vivo. 292 
However, about 30-40% of known mammalian miRNAs are located within introns of protein coding 293 
genes (5,33). Thus, the phenotype of miRNA KO animals can be influenced by the simultaneous 294 
invalidation of their hosting gene (34). To circumvent this problem, strategies avoiding to manipulate 295 
the genome and permitting direct interference with the function of the mature miRNA have been 296 
developed. In vivo delivery of miRNA sponges constitutes an interesting approach to study miRNA 297 
loss-of-function phenotypes and is emerging as a very attractive alternative to the use of KO mouse 298 
models. miRNA sponges have been demonstrated to be powerful inhibitors of miRNA activity due to  299 
the presence of multiple binding sites that sequester their target miRNA, thus preventing the 300 
interaction with their endogenous targets (24). A major advantage of this strategy is that it permits 301 
repression of miRNA activity in adult animals, avoiding problems associated with the invalidation of 302 
the miRNA during the fetal period and possible developmental defects. An efficient strategy of 303 
miRNA sponge delivery in mouse tissues is the use of viral vectors (25). In the past decade, new AAV 304 
vectors have been engineered, providing efficient gene transfer vehicles driven by tissue-specific 305 
promoters that have the tremendous advantage of lacking pathogenicity and displaying low 306 
immunogenicity (35). Studies showed that intraductal delivery of single stranded AAV vectors permits 307 
high gene transfer efficiency in endocrine islet cells (23).  308 
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Here we have combined a miRNA sponge approach with an AAV delivery strategy to study miR-338-309 
3p action in vivo. To our knowledge, this is the first study with AAV-mediated delivery of a miRNA 310 
sponge specifically in pancreatic β-cells. Our results now confirm in vivo the involvement of miR-338-311 
3p in the control of β-cell proliferation and suggest that AAV-based delivery of miR-338-3p inhibitors 312 
in diabetic animal models may represent an attractive therapeutic approach to promote the β-cell 313 
expansion and restore an appropriate mass of insulin-secreting cells. Further investigations will be 314 
required to improve the efficiency of the delivery of the sponge since under our experimental 315 
condition only a fraction of the β-cells were transduced and this was insufficient to significantly 316 
increase the total β-cell mass. An additional aspect that will need to be re-evaluated is the AAV 317 
delivery approach. Intraductal injection is a rather invasive method to deliver the sponge. In the future, 318 
it will be possible that capsid modifications in the AAV particles will allow them to target the β-cells 319 
in vivo by means of less invasive strategies such as intraperitoneal or intravenous injections. 320 
Intronic miRNAs are usually thought to be coordinately expressed with their hosting gene, suggesting 321 
that they are transcribed from a common precursor under the control of a single promoter (5,8). 322 
Consistent with the data of a previous study carried out in a neuroblastoma cell line, we found a 323 
parallel regulation of the expression of miR-338-3p and of its hosting gene AATK (11). Our findings 324 
suggest that the concomitant decrease of miR-338-3p and AATK in β-cells of animals with insulin 325 
resistance showing β-cell mass expansion involves the cAMP-dependent pathway. This observation is 326 
consistent with the activation of GPR30 or GLP1R signalling cascades that increase cAMP levels 327 
(36,37). The reduction of miR-338-3p and AATK levels elicited by these two hormones reproduced 328 
the changes observed in islets of pregnant and obese animals. Our results point to a common 329 
regulation of the expression of miR-338-3p and its hosting gene in pancreatic islets under insulin 330 
resistance conditions that involves at least in part the cAMP signaling. The possibility of a differential 331 
regulation of the level of the miRNA and its hosting gene under other specific conditions cannot be 332 
ruled out. This could potentially be achieved by the use of an alternative promoter permitting an 333 
independent transcription of miR-338-3p (38) or via post-transcriptional control mechanisms allowing 334 
a fine tuning of the level of the AATK mRNA and of miR-338-3p (39).  335 
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Thanks to its tyrosine kinase activity, AATK has been proposed to play a role in the terminal 336 
differentiation and growth of neurons as well as cell proliferation and to be involved in the apoptosis 337 
of mature neuronal and cancer cells (12-17). So far, this gene has not yet been investigated in 338 
pancreatic β-cells. In contrast to neuronal cells, the reduction of AATK in insulin-secreting cells did 339 
not impact on cell survival. This may be explained by the fact that, in contrast to miR-338-3p 340 
blockade, AATK knock-down does not lead to the up-regulation of the anti-apoptotic genes Bcl2 and 341 
Bcl-xl. However, silencing of AATK resulted in a significant increase of replicating β-cells, 342 
suggesting that its down-regulation under conditions of insulin resistance may contribute to 343 
compensatory β-cell mass expansion. This view is supported by the fact that both miR-338-3p and 344 
AATK down-regulation elicit β-cell proliferation in association with increased expression of Igf1r and 345 
Igf2 genes. In fact, these two proteins are the central components of an autocrine signaling loop that 346 
controls β-cell mass expansion under insulin resistance conditions (31,32). None of the genes 347 
differentially expressed in the presence of the anti-miRNA are predicted targets of miR-338-3p. Thus, 348 
the activation of the Igf1r/Igf2 autocrine loop observed after the reduction of the level of miR-338-3p 349 
is probably indirect. Interestingly, the inhibition of miR-338-3p has been proposed to play a prominent 350 
role in regulating the proliferation of liver and gastric cancer cells by directly targeting the 3’UTR of 351 
mRNAs encoding oncogenes and cell cycle activators (40,41). Analogous mechanisms may also 352 
contribute to the proliferative effect observed in insulin-secreting cells following the reduction of 353 
AATK or its intronic miRNA.  354 
In conclusion, we have identified miR-338-3p and it host gene AATK as candidates for gene-based 355 
therapies or drug targets for approaches aiming at promoting β-cell proliferation and β-cell mass 356 
expansion. Moreover, we have shown that the expression of miR-338-3p and AATK is regulated by 357 
common mechanisms, activates overlapping downstream signaling pathways and has similar 358 
functional impacts on insulin-secreting cells. Whether miR-338-3p and AATK have, redundant, 359 
complementary or synergetic actions in promoting β-cell mass expansion under conditions of 360 
increased insulin needs remains to be determined.   361 
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Figure legends 485 
 486 
FIGURE 1. Intraductal delivery of AAV8-miR-338-3p sponge promotes β-cell proliferation. A, 487 
Schematic representation of the construct used to specifically block the activity of miR‐338‐3p in 488 
pancreatic beta‐cells.  The multimerized binding sites present on the “sponge” selectively sequester 489 
miR‐338‐3p and prevent its interaction with its endogenous targets. The expression of the sponge is 490 
driven by the rat insulin promoter insuring beta‐cell‐specific expression of large amounts of the 491 
construct. B-I, Mice were injected intraductally with 1×10
12
 viral genomes of AAV8-control sponge or 492 
AAV8-miR-338-3p sponge. Both expression cassettes also encoded the GFP reporter gene and were 493 
driven by the rat insulin promoter. Animals were analyzed 1 month after injection. B, Quantification 494 
of transduced islets per pancreas (%). C, Quantification of transduced β‐cells per islets (%). D, 495 
Immunohistochemical analysis of GFP (green) and insulin (red) abundance in islets. Transduced cells 496 
were exclusively β-cells. E, β‐cell and non β‐cell replication was assessed by Ki67 and GFP co-497 
immunostaining (%). F, Image showing examples of double-positive Ki67+/GFP+ islet cells (Ki67 498 
staining in red; GFP+ cells in green; nuclear staining in blue). G, β‐cell replication assessed by co-499 
immunostaining with Ki67 and insulin. H, Ki67+ β-cells, red; β-cells, green; nuclei, blue; arrows 500 
indicate Ki67+ β-cells. I, β‐cell mass was measured after injection of AAV8‐control sponge or AAV8‐501 
sponge miR‐338‐3p in ICR mice by using insulin staining and weighting pancreas (mg). Results are 502 
expressed as mean ± SD; n=4‐5 animals per group. *p<0.05 was considered significant versus control.   503 
 504 
FIGURE 2. AATK expression is reduced in islets of insulin resistant animals. AATK mRNA 505 
levels were measured by qRT‐PCR in islets from pregnant rats at different stages of gestation A, 6‐506 
week‐old pre‐diabetic db/db mice B, and diet‐induced obese (DIO) mice fed a high‐fat‐diet for 8 507 
weeks C. Data are the mean ± SD from 4 animals, normalized by 18S. *p<0.05 versus control. 508 
 509 
FIGURE 3. miR-338-3p and AATK expression is reduced in INS832/13 cells treated with a 510 
cAMP-raising agent. miR-338-3p and AATK mRNA levels were measured by qRT‐PCR in 511 
24 
 
INS832/13 cells exposed to 1mM IBMX for the indicated periods. Data were normalized by 18S or 512 
U6 levels for mRNAs and miRNAs, respectively. They represent the mean ± SD from 3 independent 513 
experiments. *p<0.05 versus control. 514 
 515 
FIGURE 4. 17‐β estradiol and the GLP1‐analogue exendin‐4 elicit AATK decrease.  516 
AATK expression was measured by qRT‐PCR in rat A, C, D and human B, E islets. A, B, Islets were 517 
treated for 48h with 100 nM of 17-β estradiol, C, 100 nM of the GPR30 agonist G1 or D, E, 100 nM 518 
of the GLP1 analogue exendin-4. Data are the mean ± SD from 3 independent experiments normalized 519 
by 18S. *p<0.05 versus control. 520 
 521 
FIGURE 5. Silencing of AATK and inhibition of miR-338-3p in INS832/13 cells reproduce their 522 
decreased levels observed in islets of insulin resistant animal models. A, miR‐338‐3p expression 523 
and AATK mRNA levels were measured by qRT‐PCR three days following transfection with siGFP 524 
or siAATK, normalized by U6 or 18S. B, AATK protein levels were assessed by western blot 72h 525 
after transfection of siGFP or siAATK and normalized by tubulin. C, Western blot quantification. D, 526 
INS832/13 cells were transfected with anti-miR-338-3p or with a scrambled sequence single stranded 527 
used as an anti-miR-control. miR-338-3p expression and AATK mRNA levels were measured by 528 
qRT-PCR and normalized to U6 or 18S levels. Results represent the mean ± SD from 3‐6 independent 529 
experiments. * p<0.05 versus control.  530 
 531 
FIGURE 6. Functional role of AATK and miR-338-3p in INS832/13 cells. INS832/13 cells were 532 
transfected for 72 hours either with anti‐miR‐338‐3p (anti-338-3p), anti‐miR‐control (anti-ctrl), 533 
siAATK or siGFP as control. A, Cell replication was assessed by scoring the Ki67‐stained cells. 534 
Insulin secretion. B, and insulin content. C, in response to 2 mM glucose as basal condition (Black 535 
bars) or 20 mM glucose, 10 μM forskolin, 100μM IBMX as a cocktail for stimulatory condition (grey 536 
bars). Insulin release is expressed as percentage of insulin content (IC). D, Cells were incubated for 24 537 
hours with (+) or without (-) a mix of proinflammatory cytokines (10 ng/ml TNF-α, 0.1 ng/ml IL-1β, 538 
30 ng/ml IFN-γ) or E, for 48 hours either with 0.5% BSA (-) or with 0.5% BSA coupled to 0.5 mM 539 
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palmitate (+). D, E, Apoptosis was assessed by staining the cells with Hoechst and counting the 540 
picnotic nuclei. F, Birc5, Foxm1, Cyclin D2, Igf1r, Irs2, Bcl2, Bcl-xl, and Bad expression were 541 
measured by qRT-PCR and compared with the level in cells transfected with a scrambled antimiR or 542 
siGFP as controls. Data are expressed as fold changes. Data are expressed as mean ± SD from 3-5 543 
independent experiments. *, # p<0.05. 544 
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